A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients

被引:9
|
作者
Bark, Juliana Muller [1 ,2 ,3 ]
Karpe, Avinash V. [4 ,5 ]
Doecke, James D. [6 ]
Leo, Paul [3 ,7 ]
Jeffree, Rosalind L. [8 ,9 ,10 ,11 ]
Chua, Benjamin [9 ,12 ]
Day, Bryan W. [3 ,9 ,11 ]
Beale, David J. [4 ]
Punyadeera, Chamindie [2 ,13 ,14 ,15 ]
机构
[1] Queensland Univ Technol, Fac Hlth, Ctr Biomed Technol, Sch Biomed Sci, Brisbane, Qld, Australia
[2] Griffith Univ, Griffith Inst Drug Discovery, Saliva & Liquid Biopsy Translat Lab, Brisbane, Qld, Australia
[3] Queensland Univ Technol, Fac Hlth, Sch Biomed Sci, Gardens Point, Qld, Australia
[4] Environm Commonwealth Sci & Ind Res Org CSIRO, Ecosci Precinct, Dutton Pk, Qld, Australia
[5] Commonwealth Sci & Ind Res Org CSIRO, Agr & Food, Acton, ACT, Australia
[6] Royal Brisbane & Womens Hosp, Australian EHlth Res Ctr, Surg Treatment & Rehabil Serv STARS, CSIRO, Level 7, Herston, Qld, Australia
[7] Queensland Univ Technol, Fac Hlth, Sch Biomed Sci, Translat Genom Grp, Woolloongabba, Australia
[8] QIMR Berghofer Med Res Inst, Herston, Qld, Australia
[9] Univ Queensland, Fac Med, Herston, Qld, Australia
[10] Royal Brisbane & Womens Hosp, Kenneth G Jamieson Dept Neurosurg, Brisbane, Qld, Australia
[11] QIMR Berghofer MRI, Cell & Mol Biol Dept, Sid Faithfull Brain Canc Lab, Brisbane, Qld, Australia
[12] Royal Brisbane & Womens Hosp, Canc Care Serv, Brisbane, Qld, Australia
[13] Griffith Univ, Menzies Hlth Inst, Southport, Qld, Australia
[14] Translat Res Inst, Woolloongabba, Qld, Australia
[15] Griffith Inst Drug Discovery, Saliva & Liquid Biopsy Translat Lab, 46 Don Young Rd, Nathan, Qld 4111, Australia
来源
CANCER MEDICINE | 2023年 / 12卷 / 10期
基金
英国医学研究理事会;
关键词
blood; glioblastoma; lipids; metabolites; metabolomics; saliva; ARGININE DEPRIVATION; CANCER; BIOSYNTHESIS; GLYCOLYSIS; CHALLENGES; BIOMARKERS; PROTEIN; GROWTH; TUMORS; CELLS;
D O I
10.1002/cam4.5857
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently, no validated therapy response biomarkers are available for monitoring GBM progression. Metabolomics holds potential as a complementary tool to improve the interpretation of therapy responses to help in clinical interventions for GBM patients.Methods: Saliva and blood from GBM patients were collected pre and postoperatively. Patients were stratified conforming their progression-free survival (PFS) into favourable or unfavourable clinical outcomes (>9 months or PFS <= 9 months, respectively). Analysis of saliva (whole-mouth and oral rinse) and plasma samples was conducted utilising LC-QqQ-MS and LC-QTOF-MS to determine the metabolomic and lipidomic profiles. The data were investigated using univariate and multivariate statistical analyses and graphical LASSO-based graphic network analyses.Results: Altogether, 151 metabolites and 197 lipids were detected within all saliva and plasma samples. Among the patients with unfavourable outcomes, metabolites such as cyclic-AMP, 3-hydroxy-kynurenine, dihydroorotate, UDP and cis-aconitate were elevated, compared to patients with favourable outcomes during pre-and post-surgery. These metabolites showed to impact the pentose phosphate and Warburg effect pathways. The lipid profile of patients who experienced unfavourable outcomes revealed a higher heterogeneity in the abundance of lipids and fewer associations between markers in contrast to the favourable outcome group.Conclusion: Our findings indicate that changes in salivary and plasma metabolites in GBM patients can potentially be employed as less invasive prognostic biomarkers/biomarker panel but validation with larger cohorts is required.
引用
收藏
页码:11427 / 11437
页数:11
相关论文
共 50 条
  • [31] Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study
    Franceschi, Enrico
    Depenni, Roberta
    Paccapelo, Alexandro
    Ermani, Mario
    Faedi, Marina
    Sturiale, Carmelo
    Michiara, Maria
    Servadei, Franco
    Pavesi, Giacomo
    Urbini, Benedetta
    Pisanello, Anna
    Crisi, Girolamo
    Cavallo, Michele A.
    Dazzi, Claudio
    Biasini, Claudia
    Bertolini, Federica
    Mucciarini, Claudia
    Pasini, Giuseppe
    Baruzzi, Agostino
    Brandes, Alba A.
    JOURNAL OF NEURO-ONCOLOGY, 2016, 128 (01) : 157 - 162
  • [32] Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients
    Behm, Timo
    Horowski, Antonia
    Schneider, Simon
    Bock, Hans Christoph
    Mielke, Dorothee
    Rohde, Veit
    Stockhammer, Florian
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (10) : 2142 - 2146
  • [33] A pilot study of the metabolomic profiles of saliva from female orthodontic patients with external apical root resorption
    Zhou, Jinglin
    Hu, Huimin
    Huang, Renhuan
    CLINICA CHIMICA ACTA, 2018, 478 : 188 - 193
  • [34] Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients
    Tanaka, Shota
    Meyer, Fredric B.
    Buckner, Jan C.
    Uhm, Joon H.
    Yan, Elizabeth S.
    Parney, Ian F.
    JOURNAL OF NEUROSURGERY, 2013, 118 (04) : 786 - 798
  • [35] Differential expression of microRNAs in plasma of patients with prediabetes and newly diagnosed type 2 diabetes
    Yan, Shaoying
    Wang, Tianqiong
    Huang, Shengwen
    Di, Yanan
    Huang, Yunzhu
    Liu, Xingmei
    Luo, Zhenyuan
    Han, Wenping
    An, Bangquan
    ACTA DIABETOLOGICA, 2016, 53 (05) : 693 - 702
  • [36] Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients
    Kawabata, Shinji
    Miyatake, Shin-Ichi
    Nonoguchi, Naosuke
    Hiramatsu, Ry.
    Iida, Kyoko
    Miyata, Shiro
    Yokoyama, Kunio
    Doi, Atsushi
    Kuroda, Yuzo
    Kuroiwa, Toshihiko
    Michiue, Hiroyuki
    Kumada, Hiroaki
    Kirihata, Mitsunori
    Imahori, Yoshio
    Maruhashi, Akira
    Sakurai, Yoshinori
    Suzuki, Minoru
    Masunaga, Shin-Ichiro
    Ono, Koji
    APPLIED RADIATION AND ISOTOPES, 2009, 67 (7-8) : S15 - S18
  • [37] The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma
    Flechl, B.
    Sax, C.
    Ackerl, M.
    Crevenna, R.
    Woehrer, A.
    Hainfellner, J.
    Preusser, M.
    Widhalm, G.
    Kiesel, B.
    Lutgendorf-Caucig, C.
    Dieckmann, K.
    Steffal, C.
    Marosi, C.
    Hassler, M. R.
    RADIOTHERAPY AND ONCOLOGY, 2017, 125 (02) : 228 - 233
  • [38] The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
    Han, Seunggu J.
    Rutledge, W. Caleb
    Molinaro, Annette M.
    Chang, Susan M.
    Clarke, Jennifer L.
    Prados, Michael D.
    Taylor, Jennie W.
    Berger, Mitchel S.
    Butowski, Nicholas A.
    NEUROSURGERY, 2015, 77 (02) : 248 - 253
  • [39] Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma
    Geon An
    Stephen Ahn
    Jae-Sung Park
    Sin- Soo Jeun
    Yong- Kil Hong
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 901 - 909
  • [40] Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients
    Rigamonti, Andrea
    Imbesi, Francesca
    Silvani, Antonio
    Gaviani, Paola
    Agostoni, Elio
    Porcu, Luca
    De Simone, Irene
    Torri, Valter
    Salmaggi, Andrea
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 390 : 14 - 19